News

AF patients receive unnecessary oral anticoagulants


 

References

About a quarter of U.S. atrial fibrillation patients under 60 years old and in otherwise good health received oral anticoagulants contrary to guidelines, according to a research letter from Dr. Jonathan Hsu of the University of California, San Diego, and his associates.

In patients in the National Cardiovascular Data Registry’s PINNACLE (Practice Innovation and Clinical Excellence) registry who had a CHADS2 and CHA2DS2-VASc score of zero, the average age of those who received oral anticoagulants was just under 51 years, compared with just over 46 years for those who did not receive oral anticoagulants. In addition to age, higher body mass index and having Medicare or no insurance vs. private insurance were associated with a higher prescription chance.

Patients treated in the South were significantly less likely to be prescribed anticoagulants than were those treated in the Northeast.

“Prescription of oral anticoagulants by cardiovascular specialists in a significant proportion of patients at the lowest thrombotic risk suggests that these health care professionals may not be fully aware of the potential risks associated with oral anticoagulation or the particularly low risk of stroke in this population,” the investigators concluded. Find the full research letter in JAMA Internal Medicine (doi:10.1001/jamainternmed.2015.0920).

Recommended Reading

Cancer treatment–induced cardiotoxicity greatly underappreciated
MDedge Hematology and Oncology
Who will get cancer treatment-induced cardiotoxicity?
MDedge Hematology and Oncology
Extended use of oral anticoagulants reduces VTE recurrence
MDedge Hematology and Oncology
Edoxaban approved for atrial fib, DVT, and PE indications
MDedge Hematology and Oncology
Aromatase inhibitors linked to cardiovascular disease
MDedge Hematology and Oncology
Statins found to have a survival benefit in colorectal cancer
MDedge Hematology and Oncology
Breast cancer patients show poor adherence to cardiovascular, diabetes medications
MDedge Hematology and Oncology
Guideline recommends combination therapy for smoking cessation in cancer patients
MDedge Hematology and Oncology
Apple’s ResearchKit
MDedge Hematology and Oncology
Avoid voriconazole in transplant patients at risk for skin cancer
MDedge Hematology and Oncology